Intellia Therapeutics, Inc. (NTLA) Cash Flow Statement
Intellia Therapeutics, Inc. (NTLA) generated -$346.6M of operating cash flow over the twelve months to 2026-06-30, spent $2.0M on capital expenditure and had free cash flow of -$348.7M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
NTLAIntellia Therapeutics, Inc.Follow NTLA — free
—
Price chart with a free account
- Market cap
- 1.6B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
| Line | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -0.06 | -0.10 | -0.05 | -0.23 | -0.33 | -0.39 | -0.35 | -0.39 | -0.35 | |
| Capital expenditure | 0.01 | 0.01 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | -0.00 | |
| Free cash flow | -0.07 | -0.11 | -0.05 | -0.24 | -0.35 | -0.41 | -0.35 | -0.40 | -0.35 | |
| Stock-based compensation | 0.02 | 0.02 | 0.02 | 0.05 | 0.09 | 0.13 | 0.15 | 0.08 | — |
USD billions · SEC XBRL
Intellia Therapeutics, Inc. — questions
- What is Intellia Therapeutics, Inc.'s operating cash flow?
- -$346.6M over the twelve months to 2026-06-30.
- How much does Intellia Therapeutics, Inc. spend on capital expenditure?
- $2.0M over the twelve months to 2026-06-30.
- What is Intellia Therapeutics, Inc.'s free cash flow?
- -$348.7M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Intellia Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.